Skip to the main content

Review article

https://doi.org/10.2478/aiht-2021-72-3491

Presence of nitrosamine impurities in medicinal products

Ilijana Sedlo orcid id orcid.org/0000-0003-1673-5290 ; University of Rijeka, Department of Biotechnology, Croatia
Teo Kolonić orcid id orcid.org/0000-0002-4548-2555 ; Agency for Medicinal Products and Medical Devices (HALMED), Zagreb, Croatia
Siniša Tomić orcid id orcid.org/0000-0002-3500-9940 ; University of Rijeka, Department of Biotechnology, Croatia 2 Agency for Medicinal Products and Medical Devices (HALMED), Zagreb, Croatia


Full text: croatian pdf 259 Kb

page 5-5

downloads: 703

cite

Full text: english pdf 259 Kb

page 1-5

downloads: 509

cite


Abstract

In 2018, some sartan medicinal products were reported to be contaminated with nitrosamine compounds, which are potent mutagenic carcinogens. Two nitrosamines received particular attention: N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA). These have since been confirmed in different types of medicinal products, including ranitidine and metformin. Consequently, the European Medicines Agency (EMA) started an investigation into the cause
of contamination and an assessment of the risk to patients taking contaminated medicinal products. The main source of contamination were changes in production, which involves combinations of amines and nitrogen compounds and the use of specific catalysts and reagents. Withdrawals of medicinal products that took place in Croatia did not lead to a shortage
of sartan- or metformin-containing medicines. Moreover, ranitidine had been preventively withdrawn all over the EU, including Croatia, creating shortages at the time, but was subsequently replaced with therapeutic alternatives.

Keywords

carcinogenicity; metformin; NDEA; NDMA; ranitidine; sartans

Hrčak ID:

253743

URI

https://hrcak.srce.hr/253743

Publication date:

16.3.2021.

Article data in other languages: croatian

Visits: 3.286 *